Citizen Portal
Sign In

Get Full Government Meeting Transcripts, Videos, & Alerts Forever!

Get email alerts on the Prevention Programs topic

No spam. Unsubscribe anytime.

CPRIT oversight committee approves 15 prevention grants totaling about $27 million

Cancer Prevention and Research Institute of Texas (CPRIT) Oversight Committee · November 25, 2025
AI-Generated Content: All content on this page was generated by AI to highlight key points from the meeting. For complete details and context, we recommend watching the full video. so we can fix them.

Summary

The Cancer Prevention and Research Institute of Texas oversight committee approved 15 prevention grant recommendations covering screening, tobacco cessation and obesity‑related prevention programs, and delegated contract negotiation authority to the CEO.

The CPRIT oversight committee voted to approve the Program Integration Committee’s 15 prevention award recommendations, a slate the agency says totals about $27,000,169.50 and would fund projects across screening, tobacco cessation and primary prevention.

Miss Doyle, CPRIT’s chief executive officer, told the committee the slate would—if approved—help the agency pass a cumulative milestone of $4 billion in awards since CPRIT’s founding. Doctor Lehi (prevention program presenter) described five representative projects on the slate, including a colorectal cancer screening expansion by the University of Texas Health Science Center at Houston (serving 30 counties), a lung cancer screening and tobacco‑cessation consortium led from Baylor College of Medicine, and a community health worker coordinated breast, cervical screening and HPV vaccination program proposed by the Young Women’s Christian Association of San Antonio (a potential first CPRIT grantee for that organization).

Lehi said the prevention slate emphasized evidence‑based interventions and geographic reach: the proposed awards would add services in roughly 154 counties and serve an estimated 811,508 people across those projects. Members asked about screening innovations such as liquid biopsies; staff said those applications have not yet come through the prevention slate and that CPRIT expects to see more applications tied to new blood‑based screening science in coming years.

During discussion, committee members highlighted program monitoring and compliance supports. Mr. Nance reported compliance metrics showing improved reporting timeliness and that CPRIT had conducted 67 compliance monitoring reviews in FY25. Mr. Burgess and others emphasized training and standardized reporting as drivers of improved match documentation.

The committee carried the motion to approve all 15 prevention award slates by voice vote and delegated contract negotiation authority to the CEO and CPRIT staff to finalize awards and sign grant contracts. The oversight committee also approved the fiscal year 2027 prevention request for applications as presented.

The oversight committee’s approval is a procedural authorization; the CEO and CPRIT staff are authorized to negotiate and execute contracts under standard terms (including CPRIT’s Attachment D revenue‑sharing provisions where applicable).